头孢他洛滨-他唑巴坦和头孢他啶-阿维巴坦对β-内酰胺类耐药铜绿假单胞菌分离株的活性。
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
机构信息
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, USA.
出版信息
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
Abstract
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) MICs were evaluated for a collection of 309 beta-lactam-resistant isolates of recovered from three institutions in the area of Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% were susceptible to meropenem, 20.7% were susceptible to piperacillin-tazobactam, 24.6% were susceptible to ceftazidime, 25.9% were susceptible to cefepime, 72.5% were susceptible to C/T, and 61.8% were susceptible to CZA. Among C/T-resistant isolates, 9.1% were CZA susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T.
摘要
对从加利福尼亚州洛杉矶地区的三个机构中分离出的 309 株β-内酰胺耐药株进行了头孢洛扎他唑巴坦（C/T）和头孢他啶-阿维巴坦（CZA）的 MIC 评估。总体而言，12.0%的分离株对亚胺培南敏感，15.9%的分离株对美罗培南敏感，20.7%的分离株对哌拉西林他唑巴坦敏感，24.6%的分离株对头孢他啶敏感，25.9%的分离株对头孢吡肟敏感，72.5%的分离株对 C/T 敏感，61.8%的分离株对 CZA 敏感。在 C/T 耐药株中，9.1%的分离株对 CZA 敏感，而 36.4%的 CZA 耐药株对 C/T 敏感。
相似文献
1
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.头孢他洛滨-他唑巴坦和头孢他啶-阿维巴坦对β-内酰胺类耐药铜绿假单胞菌分离株的活性。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
2
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
3
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.头孢洛扎/他唑巴坦与头孢他啶/阿维巴坦对大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌多重耐药菌株抗菌活性的比较。
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
4
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.头孢他洛滨他唑巴坦与传统β-内酰胺类药物的比较以及头孢他洛滨他唑巴坦作为铜绿假单胞菌联合抗菌治疗替代方案的比较。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
5
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.体外研究头孢洛扎他唑巴坦和头孢他啶-阿维巴坦对耐美罗培南铜绿假单胞菌临床分离株的活性：一项多中心研究。
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
6
Assessment of the Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Clinical Isolates at Montpellier University Hospital, France.法国蒙彼利埃大学医院收集的产β-内酰胺酶肠杆菌科和临床分离株中头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦活性的评估。
Microb Drug Resist. 2019 Nov;25(9):1325-1329. doi: 10.1089/mdr.2018.0439. Epub 2019 Jun 21.
7
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.2014年美国各医疗中心当代铜绿假单胞菌分离株对头孢他啶-阿维巴坦的体外活性：按普查区域划分
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.
8
Integrated Genome-Wide Analysis of an Isogenic Pair of Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.临床分离株对头孢洛扎他唑巴坦、头孢他啶/阿维巴坦和哌拉西林/他唑巴坦的抗菌药物耐药性差异的同源对全基因组综合分析。
Int J Mol Sci. 2020 Feb 4;21(3):1026. doi: 10.3390/ijms21031026.
9
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.ERACE-PA 全球监测计划：头孢他啶/他唑巴坦和头孢他啶/阿维巴坦对全球碳青霉烯类耐药铜绿假单胞菌的体外活性。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541. doi: 10.1007/s10096-021-04308-0. Epub 2021 Jul 22.
10
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
引用本文的文献
1
Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.新生儿多重耐药革兰阴性菌败血症：头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦的特殊作用
Medicines (Basel). 2025 Jun 26;12(3):17. doi: 10.3390/medicines12030017.
2
Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦对耐碳青霉烯类铜绿假单胞菌临床分离株的体外抗菌活性评估。
BMC Infect Dis. 2025 Apr 28;25(1):622. doi: 10.1186/s12879-025-10891-w.
3
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.革兰氏阴性菌对头孢他啶-阿维巴坦耐药性的全球趋势：系统评价与荟萃分析
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
4
Guidelines for Antibiotics Prescription in Critically Ill Patients.重症患者抗生素处方指南
Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S104-S216. doi: 10.5005/jp-journals-10071-24677. Epub 2024 Aug 10.
5
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.土耳其碳青霉烯类耐药铜绿假单胞菌临床分离株中头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦和头孢地尔的药敏谱。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1787-1794. doi: 10.1007/s10096-024-04896-7. Epub 2024 Jul 12.
6
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and .新型β-内酰胺/β-内酰胺酶抑制剂对耐碳青霉烯类肠杆菌科细菌感染的抗菌及诊断管理
Antibiotics (Basel). 2024 Mar 21;13(3):285. doi: 10.3390/antibiotics13030285.
7
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.临床实验室中新型β-内酰胺类及β-内酰胺类联合制剂的检测方法
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
8
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.用于治疗儿童多重耐药革兰氏阴性菌感染的新型β-内酰胺类抗生素：一项叙述性综述
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
9
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.头孢洛扎他唑巴坦与头孢他啶-阿维巴坦治疗多重耐药铜绿假单胞菌感染的疗效比较：一项多中心队列研究。
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0040523. doi: 10.1128/aac.00405-23. Epub 2023 Jul 5.
10
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.最新一代β-内酰胺/β-内酰胺酶抑制剂联合疗法对多重耐药铜绿假单胞菌的活性。
Sci Rep. 2022 Oct 7;12(1):16814. doi: 10.1038/s41598-022-21101-x.
本文引用的文献
1
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.头孢洛扎他唑巴坦治疗多重耐药铜绿假单胞菌感染：临床疗效和耐药演变。
Clin Infect Dis. 2017 Jul 1;65(1):110-120. doi: 10.1093/cid/cix182.
2
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.多中心评估头孢他啶-阿维巴坦和头孢洛扎坦-他唑巴坦对血液、呼吸道和伤口来源的美罗培南不敏感铜绿假单胞菌的抑制活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
3
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.头孢洛扎/他唑巴坦对来自不列颠群岛的监测菌及“问题”肠杆菌科细菌、铜绿假单胞菌和非发酵菌的活性。
J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.
4
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.头孢洛扎/他唑巴坦对美国医院铜绿假单胞菌临床分离株的活性：2012年至2015年PACTS抗菌监测项目报告
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00465-17. Print 2017 Jul.
5
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.多中心评价头孢他啶/他唑巴坦治疗碳青霉烯类耐药铜绿假单胞菌所致严重感染。
Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.
6
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).头孢洛扎/他唑巴坦对引起欧洲尿路感染和腹腔内感染的耐药肠杆菌科细菌及铜绿假单胞菌的活性：一项抗菌药物监测计划（2012 - 2015年）的报告
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009.
7
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.头孢洛扎坦-他唑巴坦和头孢他啶-阿维巴坦对一组耐β-内酰胺革兰氏阴性菌的敏感性
Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.
8
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.2012年至2014年在美国医疗中心对从尿路感染患者中分离出的革兰氏阴性菌进行头孢他啶-阿维巴坦及对照药物抗菌活性研究
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4355-60. doi: 10.1128/AAC.00405-16. Print 2016 Jul.
9
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
10
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
Zotero 插件